The global botanical and plant-derived drugs market is expected to grow at a CAGR of 6.8%

LONDON, Fev. 5, 2018 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/5308405 Report Details The global botanical and plant-derived drugs market is expected to grow at a CAGR of 6.8% in the first half of the forecast period. In 2016, the phenols submarket held 30.2% of the global botanical and plant-derived drugs market. How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 164-page report you will receive 70 tables and 82 figures– all unavailable elsewhere. The 164-page report provides clear detailed insight into the global botanical and plant-derived drugs market. Discover the key drivers and challenges affecting the market. By ordering and reading our brand new report today you stay better informed and ready to act. Report Scope • Global Botanical and Plant-derived Drugs Market forecast to 2027 This report also breaks down the revenue forecast for global botanical and plant-derived drugs market by type: - Steroids - Phenols - Terpenes - Glycosides - Others This report provides a SWOT analysis for each submarket. This report also breaks down the revenue forecast for global botanical and plant-derived drugs market by application: - Hormone Diseases - Infectious Diseases - Pain & Central Nervous System Disorders - Cardiovascular & Metabolic Diseases - Respiratory & Oncology Diseases • Our work also shows individual revenue forecasts to 2027 for these regional and national markets - North America: US & Canada - Europe: Germany, France, the UK, Italy, Spain, Rest of Europe - Asia-Pacific: China, Japan, India, Rest of APAC - Latin America: Brazil, Mexico, Rest of Latin America - Middle East & Africa: Saudi Arabia, South Africa, Rest of Middle East & Africa Each regional market if further segmented by type and by application. This report discusses several brands, including: - Sativex (GW Pharmaceuticals) - Marinol (Unimed Pharmaceuticals) - Nabilone / Cesamet (Valeant Pharmaceuticals) - Dexanabinol (Solvay Pharmaceuticals, acquire by Abbott Laboratories) - CT-3 (Indevus Pharmaceuticals) - Cannabinor (Pharmos) - HU 308 (Pharmos) - HU 331 (Cayman Chemical) - Rimonabant / Acomplia (Sanofi-Aventis) - Taranabant / MK-0364 (Merck & Co.) This report assesses several leading companies that manufacture and market botanical and plant-derived drugs, including: - Abbott Laboratories - Bayer AG - Eli Lilly - Johnson & Johnson - Novartis AG - Pfizer, Inc. - Bristol-Myers Squibb (BMS) - Medigene AG • This report also discusses the Drivers and Restraints of the global botanical and plat derived-drugs market. Visiongain's study is for everybody needing commercial analyses for the global botanical and plat derived-drugs market. You will find data, trends and predictions. Please order our report now.Download the full report: https://www.reportbuyer.com/product/5308405 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected]  Tel: +1 (718) 213 4904 Website: www.reportbuyer.com   

Advertisement

View original content:http://www.prnewswire.com/news-releases/the-global-botanical-and-plant-derived-drugs-market-is-expected-to-grow-at-a-cagr-of-68-300593464.html

SOURCE ReportBuyer